Hepatotoxicity during treatment for tuberculosis in people living with HIV/AIDS

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Araújo Mariz, Carolline ^a   Lopes, Edmundo Pessoa ^a   Acioli Santos, Bartolomeu ^b   Maruza, Magda ^c   Montarroyos, Ulisses Ramos ^d   De Ximenes, Ricardo Arraes Alencar ^a,e   Lacerda, Heloísa Ramos ^a   Miranda Filho, Demócrito De Barros ^e   De Militão De Albuquerque, Maria Fátima P ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c State Health Secretariat of Pernambuco   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^e UNIVERSIDADE DE PERNAMBUCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ARYLAMINE ACETYLTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; COTRIMOXAZOLE; CYTOCHROME P450 2E1; ETHAMBUTOL; FLUCONAZOLE; GANCICLOVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS C ANTIBODY; HLA DQA1 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ISONIAZID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFADIAZINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; TUBERCULOSTATIC AGENT; NAT2 PROTEIN, HUMAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; BLOOD SAMPLING; BODY MASS; BRAZIL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; DYSPEPSIA; EUTROPHIA; FEMALE; GENOTYPE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; JAUNDICE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NAUSEA; OBESITY; OPPORTUNISTIC INFECTION; PHENOTYPE; PREDICTIVE VALUE; PROSPECTIVE STUDY; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN COLOR; SYMPTOM; TREATMENT DURATION; TUBERCULOSIS; VOMITING; ACETYLATION; COMPLICATION; DRUG EFFECTS; GENETICS; LIFESTYLE; LIVER; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; TIME FACTOR; TOXIC HEPATITIS; YOUNG ADULT;

ACETYLATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; GENOTYPE; HUMANS; LIFE STYLE; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84976577936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157725     Document Type: Article

References (40)

1. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. for the AIDS Clinical Trials Group Study A5221: Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis. N Engl J Med 2011, 365:1482-91.
2. Coca NSM, Oliveira MS, Voieta I, Antunes CMF, Lambertucci JR. Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency vírus seropositivity. Rev Soc Bras Med Trop 2010, 43(6):624-628. PMID: 21181011
3. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008, 23(2):192-202. PMID: 17995946
4. El-Sadr WM, Tsiouris SJ. HIV-associated tuberculosis: diagnostic and treatment challenges. Semin Respir Crit Care Med 2008, 29:525-531. doi: 10.1055/s-0028-1085703 PMID: 18810685
5. Breen RAM, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thoraxjnl 2006, 61:791-794.
6. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007, 21(10): 1301-1308. PMID: 17545706
7. Teixeira RLF, Morato RG, Cabello PH, Muniz LMK, Moreira ASR, Kritski AL, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. MEM INST OSWALDO CRUZ 2011, 106(6): 716-724. PMID: 22012226
8. Makhlouf HA, Helmy A, Fawzy E, El-Attar M, Rashed HAG. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol Int 2008, 2: 353-360. doi: 10.1007/s12072-008-9085-y PMID: 19669265
9. Marzuki OA, Fauzi ARM, Ayoub S, Kamarul IM. Prevalence and risk factors of anti-tuberculosis druginduced hepatitis in Malaysia. Singapore Med J 2008, 49(9): 688-693. PMID: 18830542
10. Anand AC, Seth AK, Paul M, Puri P. Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment. MJAFI 2006, 62: 45-49.
11. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis Drug-induced Hepatotoxicity: The Role of Hepatitis C Virus and the Human Immunodeficiency Virus. Am J Respir Crit Care Med 1998, 157: 1871-1876. PMID: 9620920
12. Singla N, Gupta D, Birbian N, Singh J. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis 2014, 94: 293-298. doi: 10.1016/j.tube. 2014.02.003 PMID: 24637014
13. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug-Induced Hepatitis. Hepatology 2003, 37: 924-930. PMID: 12668988
14. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002, 166: 916-919. PMID: 12359646
15. Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, Silva CA, Vallinoto AC, Fernandes DC, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis 2013, 17(4): 499-504. doi: 10.5588/ijtld.12.0645 PMID: 23394127
16. Costa GN, Magno LA, Santana CV, Konstantinovas C, Saito ST, Machado M, et al. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther 2012, 16(4):241-50. PMID: 22788240
17. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008, 64(7):673-81. doi: 10.1007/s00228-008-0484-8 PMID: 18421452
18. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Boletim epidemiológico-O controle da tuberculose no Brasil: avanços, inovações e desafios. Vol.45. N° 02-2014. Brasília: Ministério da Saúde, 2014. Available: http://portalsaude.saude.gov.br/images/ pdf/2014/maio/29/BE-2014-2-tb.pdf. Accessed 7 September 2014.
19. Carvalho CN, Dourado I, Bierrenbach AL. Underreporting of the tuberculosis and AIDS comorbidity: an application of the linkage method. Rev Saude Publica 2011, 45(3):548-55. PMID: 21503555
20. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Manual de recomendações para o controle da tuberculose no Brasil. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica. Brasília, Ministério da Saúde, 2011.
21. Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011, 6 (12):e27810. doi: 10.1371/journal.pone.0027810 PMID: 22162992
22. Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, et al. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients. PLoS One 2014, 9(4):e94271. doi: 10.1371/journal.pone.0094271 PMID: 24714066
23. Mo P, Zhu Q, Teter C, Yang R, Deng L, Yan Y, et al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis 2014, 28:95-100. doi: 10.1016/j.ijid.2014.06.020 PMID: 25218771
24. Mankhatitham W, Lueangniyomkul A, Manosuthi W. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. Southeast Asian J Trop Med Public Health 2011, 42(3):651-8. PMID: 21706943
25. Sabbagh A, Darlu P. Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genetics 2005, 6:30. PMID: 15932650
26. Zaverucha-do-Valle C, Monteiro SP, El-Jaick KB, Rosadas LA, Costa MJ, Quintana MS, et al. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients. Tuberculosis (Edinb) 2014, 94 (3):299-305.
27. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990, 11: 272-276. PMID: 2254635
28. Úriz J, Repáraz J, Castiello J, Sola J. Tuberculosis in patients with HIV infection. An Sist Sanit Navar 2007, 30(Suppl 2): 131-142. PMID: 17898833
29. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975, 18(1):70-79. PMID: 1149365
30. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006, 62(6):423-429. PMID: 16770646
31. Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One 2012, 7(10):e47769. doi: 10.1371/journal.pone.0047769 PMID: 23082213
32. Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol 2013, 28(8):1368-74. doi: 10.1111/jgh.12194 PMID: 23875638
33. Pukenyte E, Lescure FX, Rey D, Rabaud C, Hoen B, Chavanet P, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2007, 11(1):78-84. PMID: 17217134
34. Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic Review and Meta-Analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal Infection. Antimicrob Agents Chemother 2010, 54 (6): 2409-2419. doi: 10.1128/AAC.01657-09 PMID: 20308378
35. Scevola D, Matteo DA, Uberti F, Minoia G, Poletti F, Faga A. Reversal of cachexia in patients treated with potent antiretroviral. AIDS Read 2000, 10(6):365-75. PMID: 10881368
36. Macallan DC. Nutrition and immune function in human immunodeficiency virus infection. Proc Nutr Soc 1999, 58:743-48. PMID: 10604211
37. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep. 1987, 36(Suppl 1): 1S-15S.
38. Sieleunou I, Souleymanou M, Schönenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health 2009, 14:36-43.
39. Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi BU, Salkeen S. Hepatotoxicity with antituberculosis drugs: the risk factors. Pak J Med Sci 2007, 23:33-38.
40. Hassen Ali A, Belachew T, Yami A, Ayen WY. Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study. PLoS ONE 2013, 8(5): e64622. doi: 10.1371/journal.pone.0064622 PMID: 23696901